Alamar Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALMR | LAB | NEOG | CTKB | BIO | QSI | |
|---|---|---|---|---|---|---|
| Market cap | 1.68B | 258.24M | 2.62B | 690.21M | 9.74B | 297.68M |
| P/E (TTM) | — | — | — | — | 46.2 | — |
| Forward P/E | -44.7 | -65.8 | 28.8 | 75.9 | 36.7 | -3.9 |
| Price/book | 5.4 | 0.5 | 1.3 | 2.1 | 1.4 | 1.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +10.18% | −48.84% | +99.16% | +37.12% | +20.56% | −26.44% |
| Today | −4.08% | −4.58% | +1.27% | −2.21% | −0.48% | −11.11% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All ALMR news ›Alamar Biosciences rises 9.4%
Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02. Published first on TheFly – the ultimate source for real-time, market-moving breaking... Alamar Biosciences rises 9.4% Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02.…
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the appointment of Bob Ragusa to its board of ... Alamar Biosciences Names Former Grail CEO…
Alamar Biosciences price target raised to $31 from $30 at BofA
BofA raised the firm’s price target on Alamar Biosciences (ALMR) to $31 from $30 and keeps a Neutral rating on the shares. A “strong” Q2 report ... Alamar Biosciences price target raised to $31 from $30 at BofA BofA raised the firm’s price…
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Management's webcast starts at 4:30 p.m. Eastern, with live audio on Alamar's website; a replay will be available after the event. - Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 Alamar Biosciences…
Alamar: The Consumables Flywheel Is Just Getting Started
Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. Learn more about ALMR stock here. - Alamar Biosciences is rated a buy, targeting a recurring consumables-driven…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
markets.businessinsider.com4
-
stocktitan.net2
-
globenewswire.com1
-
ibtimes.com.au1
-
manilatimes.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.